Amit Deshpande
About Amit Deshpande
Amit Deshpande serves as the Senior Director of Preclinical Development at Mythic Therapeutics, Inc., bringing extensive expertise in in vivo models and translational research. He has held various significant roles in the pharmaceutical industry and academia, contributing to advancements in immuno-oncology and pharmacology.
Work at Mythic Therapeutics
Amit Deshpande currently serves as the Senior Director of Preclinical Development at Mythic Therapeutics, Inc. since 2021. In this role, he oversees the preclinical development processes, leveraging his extensive background in pharmacology and translational research. His expertise includes managing external collaborations and interactions with academia and Contract Research Organizations (CROs), which are crucial for advancing therapeutic candidates through the development pipeline.
Education and Expertise
Amit Deshpande holds a Doctor of Philosophy in Genetics and Biology from Chatrapati Sahuji Maharaj Kanpur University, where he studied from 1999 to 2003. He also completed his undergraduate studies at Bharati Vidyapeeth College of Pharmacy from 1993 to 1997. His educational background is complemented by in vivo expertise, including work with xenografts, patient-derived xenografts (PDX), and genetically engineered mouse models (GEMMs).
Professional Background
Amit Deshpande has held various positions in the biotechnology and pharmaceutical sectors. Prior to his current role, he worked at Nuvalent, Inc. as Director for one year and at EMD Serono, Inc. as Group Leader and Associate Director in Translational Biomarkers for four years. His experience also includes roles at UCLA Medical Center, Jounce Therapeutics, Five Prime Therapeutics, and Tufts-New England Medical Center, where he contributed to research and development initiatives.
Research Contributions and Publications
Amit Deshpande has contributed to the scientific community through various research initiatives. He co-authored a journal article on MYTX-011, a pH-dependent anti-cMET antibody-drug conjugate, published in April 2024. Additionally, he has participated in significant conferences, including the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023 and the American Association of Cancer Research (AACR) Annual Meeting in April 2023, where he contributed to presentations.
Mentorship and Teaching Experience
Amit Deshpande has a history of mentorship and teaching within academic settings. He served as an Assistant Researcher and Lecturer at UCLA Medical Center and has been involved in delivering platform presentations both domestically and internationally. His commitment to education and mentorship reflects his dedication to fostering the next generation of scientists in the field.